Caribou Biosciences, Inc. (NASDAQ:CRBU) Given Average Recommendation of “Buy” by Brokerages

Shares of Caribou Biosciences, Inc. (NASDAQ:CRBU) have been given an average recommendation of “Buy” by the five analysts that are covering the firm, MarketBeat reports. Five equities research analysts have rated the stock with a buy recommendation. The average 1 year target price among analysts that have issued a report on the stock in the last year is $10.33.

Several research firms have issued reports on CRBU. HC Wainwright restated a “buy” rating and issued a $9.00 price objective on shares of Caribou Biosciences in a research note on Wednesday, March 19th. Bank of America reduced their price objective on shares of Caribou Biosciences from $13.00 to $11.00 and set a “buy” rating for the company in a research report on Tuesday, January 7th.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of CRBU. PFM Health Sciences LP raised its position in shares of Caribou Biosciences by 5.5% in the third quarter. PFM Health Sciences LP now owns 4,306,671 shares of the company’s stock valued at $8,441,000 after buying an additional 223,299 shares during the last quarter. JPMorgan Chase & Co. grew its holdings in Caribou Biosciences by 475.9% in the 4th quarter. JPMorgan Chase & Co. now owns 2,495,922 shares of the company’s stock valued at $3,969,000 after buying an additional 2,062,563 shares during the period. Schonfeld Strategic Advisors LLC increased its stake in shares of Caribou Biosciences by 28.4% during the 4th quarter. Schonfeld Strategic Advisors LLC now owns 2,113,272 shares of the company’s stock valued at $3,360,000 after acquiring an additional 467,738 shares during the last quarter. Geode Capital Management LLC lifted its holdings in shares of Caribou Biosciences by 6.5% during the 3rd quarter. Geode Capital Management LLC now owns 2,030,443 shares of the company’s stock worth $3,980,000 after acquiring an additional 124,782 shares during the period. Finally, FMR LLC lifted its holdings in shares of Caribou Biosciences by 7.4% during the 3rd quarter. FMR LLC now owns 1,581,493 shares of the company’s stock worth $3,100,000 after acquiring an additional 109,606 shares during the period. 77.51% of the stock is owned by hedge funds and other institutional investors.

Caribou Biosciences Stock Up 12.2 %

CRBU opened at $0.99 on Friday. The firm has a market cap of $91.95 million, a P/E ratio of -0.60 and a beta of 2.34. Caribou Biosciences has a 52 week low of $0.88 and a 52 week high of $5.23. The business has a fifty day simple moving average of $1.25 and a 200-day simple moving average of $1.71.

Caribou Biosciences (NASDAQ:CRBU) last released its earnings results on Monday, March 10th. The company reported ($0.39) EPS for the quarter, topping the consensus estimate of ($0.40) by $0.01. The firm had revenue of $2.08 million during the quarter, compared to analysts’ expectations of $2.11 million. Caribou Biosciences had a negative return on equity of 45.46% and a negative net margin of 1,290.81%. Sell-side analysts expect that Caribou Biosciences will post -1.64 earnings per share for the current year.

About Caribou Biosciences

Caribou Biosciences, Inc, a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma.